Published: Jeffrey Cummings

Dr. Jeffery Cummings (Brain Health) and other members of a joint European Union/United States Task Force recently published, “The Future of Anti-Amyloid Trials,” in the Journal of Prevention and Alzheimer’s Disease. The authors analyze the impact of multiple clinical trials that recently ended for a variety of reasons on the Alzheimer's disease clinical research enterprise. The task force concludes the study of amyloid proteins, while complex, remains a worthwhile undertaking and should not be the only target of clinical trials.They offer several recommendations in the trial design to optimize the potential benefits and reduce potential risks to participants as much as possible.

People in the News

man in scrubs in medical storage room
People | November 20, 2020
COVID-19 has rerouted but not derailed Dr. Arthur Romero’s work to improve lung cancer patient outcomes.
a woman working at a ligtboard
People | November 16, 2020
This math professor strives to find teaching methods that encourage students to enjoy math and pursue further studies.
People | November 12, 2020
First-generation alumnus learned to navigate his way to a degree by continually asking questions.